Acute Myeloid Leukemia (AML) Snapshot

The unmet need in AML continues to be quite high, despite the advances in cancer research.

March 2021

Sugandh Sharma, Jatin Gupta and Shweta Srivastava

Introduction

AML accounts for ~1.1% of all new cancer cases in the US¹
The age-standardized incidence rate of AML was 1.54 per 100,000 globally and 4.3 per 100,000 in the US in 2017²
The age-standardized death rate of AML was 1.28 per 100,000 globally in 2017 and the five-year relative survival rate was 28.7%^1,2
Medicare expenses for the treatment of AML in 2019 totaled $587,700, with ~65% of the cost being for end-of-life treatments³
The medical services cost of leukemias in the US is expected to grow by 49% from 2015 to 2030³

Current and Evolving Trends in the AML Treatment Paradigm

Emerging segments and therapeutic options will further shape the AML treatment landscape

The AML Treatment Paradigm Is Evolving

With a spate of approvals within the last few years, more options are now available; however, several white spaces remain, and identifying the right patient population for the approved options is challenging.

Upcoming Catalyst Events Impacting AML Treatment: 2021-2023

Key data readouts and upcoming filings are likely to change the AML landscape; newer biomarker segments are likely to emerge.

Upcoming Catalyst Events Impacting AML Treatment: 2021-2023

The unmet need in AML continues to be quite high. despite the advances in cancer research. The key requirement is for a more effective treatment that reduces the high rate of relapsed/refractory disease in AML⁴. The emerging treatment options focus on biomarkers, such as FLT3, CD33, RARA+ and TP53, and show promise for specific sub-groups of patients. A similar trend is being observed for the relapsed/refractory segment as well, with multiple promising therapies in development; however, only time will tell whether these therapies can reduce the burden of the disease.

Sources

https://seer.cancer.gov/statfacts/html/amyl.html
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00908-z#Tab2
https://cebp.aacrjournals.org/content/29/7/1304
https://pubmed.ncbi.nlm.nih.gov/30132678/#:~:text=Several%20unmet%20needs%20exist%20in,to%20reduce%20relapse%20are%20important